首页 > 最新文献

Central European Journal of Urology最新文献

英文 中文
The effect of percussion, diuresis and inversion therapy on RIRS success for lower renal pole stones. 叩击、利尿和反转疗法对下肾极结石 RIRS 成功率的影响。
IF 1.2 Q3 Medicine Pub Date : 2023-01-01 Epub Date: 2023-11-13 DOI: 10.5173/ceju.2023.189
Caglar Sarioglu, Samet Senel, Emre Uzun, Muhammed Emin Polat, Kazim Ceviz, Oner Odabas, Antonios Koudonas

Introduction: Inversion of the patient, forced diuresis after hydration, and mechanical percussion technique was developed for lower renal pole (LRP) stones with extracorporeal shock wave (ESWL). In this study, we aimed to analyze the effect of percussion, diuresis and inversion (PDI) therapy on the success rates of retrograde intrarenal surgery (RIRS) for the LRP stones.

Material and methods: 114 patients who underwent RIRS for LRP stones <2cm were included in this study. Patients' demographic, clinical, radiological and anatomical features and success status were recorded prospectively. The patients were divided into two groups. One group received RIRS procedure only (non-PDI group) and the other group received PDI therapy after the RIRS procedure (PDI group).

Results: PDI was performed to 60 (52.6%) patients, and not performed to 54 (47.4%) patients. The success rate (58.3%) for the PDI group was higher than the non-PDI group (25.9%), and this difference was statistically significant (p <0.001). In multivariate logistic regression analysis, stone size (OR = 1.306; 95% CI = 1.019-1.674; p <0.001), IU (OR = 1.702; 95% CI = 1.383-2.096; p <0.001) and not performing PDI therapy (p <0.001) OR = 9.455; 95% Cl = 2.426-10.853; p = 0.001) were revealed to be independent risk factors for failure.

Conclusions: PDI therapy increases the success rates of RIRS performed for the LRP stones.

简介:体外冲击波(ESWL)治疗下肾极(LRP)结石的方法包括倒转患者、水化后强制利尿和机械叩击技术。在这项研究中,我们旨在分析叩击、利尿和反转(PDI)疗法对逆行肾内手术(RIRS)治疗 LRP 结石成功率的影响:60例(52.6%)患者接受了PDI治疗,54例(47.4%)患者未接受PDI治疗。PDI 组的成功率(58.3%)高于非 PDI 组(25.9%),且差异具有统计学意义(P 结论:PDI 治疗可提高 LRP 结石的成功率:PDI疗法提高了针对LRP结石实施RIRS的成功率。
{"title":"The effect of percussion, diuresis and inversion therapy on RIRS success for lower renal pole stones.","authors":"Caglar Sarioglu, Samet Senel, Emre Uzun, Muhammed Emin Polat, Kazim Ceviz, Oner Odabas, Antonios Koudonas","doi":"10.5173/ceju.2023.189","DOIUrl":"10.5173/ceju.2023.189","url":null,"abstract":"<p><strong>Introduction: </strong>Inversion of the patient, forced diuresis after hydration, and mechanical percussion technique was developed for lower renal pole (LRP) stones with extracorporeal shock wave (ESWL). In this study, we aimed to analyze the effect of percussion, diuresis and inversion (PDI) therapy on the success rates of retrograde intrarenal surgery (RIRS) for the LRP stones.</p><p><strong>Material and methods: </strong>114 patients who underwent RIRS for LRP stones <2cm were included in this study. Patients' demographic, clinical, radiological and anatomical features and success status were recorded prospectively. The patients were divided into two groups. One group received RIRS procedure only (non-PDI group) and the other group received PDI therapy after the RIRS procedure (PDI group).</p><p><strong>Results: </strong>PDI was performed to 60 (52.6%) patients, and not performed to 54 (47.4%) patients. The success rate (58.3%) for the PDI group was higher than the non-PDI group (25.9%), and this difference was statistically significant (p <0.001). In multivariate logistic regression analysis, stone size (OR = 1.306; 95% CI = 1.019-1.674; p <0.001), IU (OR = 1.702; 95% CI = 1.383-2.096; p <0.001) and not performing PDI therapy (p <0.001) OR = 9.455; 95% Cl = 2.426-10.853; p = 0.001) were revealed to be independent risk factors for failure.</p><p><strong>Conclusions: </strong>PDI therapy increases the success rates of RIRS performed for the LRP stones.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflection points in urology as witnessed by Mark Soloway Part 2: Prostate and kidney cancers. 马克-索洛维见证的泌尿外科拐点 第二部分:前列腺癌和肾癌。
IF 1.2 Q3 Medicine Pub Date : 2023-01-01 Epub Date: 2023-11-25 DOI: 10.5173/ceju.2023.3E
Mark S Soloway
{"title":"Inflection points in urology as witnessed by Mark Soloway Part 2: Prostate and kidney cancers.","authors":"Mark S Soloway","doi":"10.5173/ceju.2023.3E","DOIUrl":"10.5173/ceju.2023.3E","url":null,"abstract":"","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation after radical prostatectomy in elderly patients - a SEER database-derived competing-risk survival analysis of propensity score-matched age groups. 老年患者根治性前列腺切除术后的放射治疗--对倾向评分匹配年龄组的 SEER 数据库衍生竞争风险生存分析。
IF 1.2 Q3 Medicine Pub Date : 2023-01-01 Epub Date: 2023-11-13 DOI: 10.5173/ceju.2023.144
Piotr Zapała, Aleksander Ślusarczyk, Łukasz Zapała, Tomasz Borkowski, Paweł Rajwa, Grzegorz Niemczyk, Piotr Radziszewski

Introduction: This study aimed to evaluate cancer-specific (CSM) and other-cause mortality (OCM) in elderly patients with prostate cancer treated with radical prostatectomy (RP) and postoperative radiotherapy (RT).

Material and methods: The Surveillance, Epidemiology, and End Results (SEER) database was searched for clinically non-metastatic prostate cancer (PCa) treated with RT after RP between 2010 and 2015. Patients were stratified according to age groups and underwent propensity score (PS) matching. The Kaplan-Meier method and competing-risk Cox regression (CRR) were used for survival analysis.

Results: In total, 5385 patients were analysed, including 738 (13.7%) elderly patients (≥70 years old) and 4647 (86.29%) younger individuals. A total of 54 (7.32%) and 69 (9.35%) patients aged ≥70 years died due to PCa and competing reasons, respectively. Among younger patients these included 275 (5.92%) and 208 (4.48%) deaths, respectively. At a median follow-up of 80 months, patients ≥70 years old had significantly shorter OCM (p <0.0001) than PS-matched younger controls without significant impairment of cancer-specific survival when compared to controls (p = 0.19). In CRR analysis older patients were at significantly higher risk of OCM (HR = 2.24, p = 0.0002 and HR = 3.3, p = 0.011 for patients aged ≥70 and ≥75 years, respectively). Simultaneously, the CRR revealed no increased risk of CSM for patients older than 70 and 75 years (HR = 1.2, p = 0.33 and HR = 1.53, p = 0.29, respectively).

Conclusions: Elderly patients with PCa are at high risk of dying due to competing reasons, which might prevent the survival benefit of RT after RP. Selection for salvage and adjuvant RT in these individuals should be cautious.

导言:本研究旨在评估接受根治性前列腺切除术(RP)和术后放疗(RT)治疗的老年前列腺癌患者的癌症特异性死亡率(CSM)和其他原因死亡率(OCM):在监测、流行病学和最终结果(SEER)数据库中搜索了2010年至2015年间接受根治性前列腺切除术(RP)和术后放疗(RT)治疗的临床非转移性前列腺癌(PCa)患者。根据年龄组对患者进行分层,并进行倾向评分(PS)匹配。采用卡普兰-梅耶法和竞争风险考克斯回归法(CRR)进行生存分析:共分析了 5385 名患者,其中包括 738 名(13.7%)老年患者(≥70 岁)和 4647 名(86.29%)年轻患者。共有 54 名(7.32%)和 69 名(9.35%)年龄≥70 岁的患者分别死于 PCa 和其他原因。年轻患者中分别有 275 人(5.92%)和 208 人(4.48%)死亡。在中位随访 80 个月时,≥70 岁患者的 OCM 明显更短(p 结论:≥70 岁患者的 OCM 明显更短(p):老年 PCa 患者因其他原因死亡的风险很高,这可能会阻碍 RP 后 RT 的生存获益。对这些患者选择挽救性和辅助性 RT 时应谨慎。
{"title":"Radiation after radical prostatectomy in elderly patients - a SEER database-derived competing-risk survival analysis of propensity score-matched age groups.","authors":"Piotr Zapała, Aleksander Ślusarczyk, Łukasz Zapała, Tomasz Borkowski, Paweł Rajwa, Grzegorz Niemczyk, Piotr Radziszewski","doi":"10.5173/ceju.2023.144","DOIUrl":"10.5173/ceju.2023.144","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate cancer-specific (CSM) and other-cause mortality (OCM) in elderly patients with prostate cancer treated with radical prostatectomy (RP) and postoperative radiotherapy (RT).</p><p><strong>Material and methods: </strong>The Surveillance, Epidemiology, and End Results (SEER) database was searched for clinically non-metastatic prostate cancer (PCa) treated with RT after RP between 2010 and 2015. Patients were stratified according to age groups and underwent propensity score (PS) matching. The Kaplan-Meier method and competing-risk Cox regression (CRR) were used for survival analysis.</p><p><strong>Results: </strong>In total, 5385 patients were analysed, including 738 (13.7%) elderly patients (≥70 years old) and 4647 (86.29%) younger individuals. A total of 54 (7.32%) and 69 (9.35%) patients aged ≥70 years died due to PCa and competing reasons, respectively. Among younger patients these included 275 (5.92%) and 208 (4.48%) deaths, respectively. At a median follow-up of 80 months, patients ≥70 years old had significantly shorter OCM (p <0.0001) than PS-matched younger controls without significant impairment of cancer-specific survival when compared to controls (p = 0.19). In CRR analysis older patients were at significantly higher risk of OCM (HR = 2.24, p = 0.0002 and HR = 3.3, p = 0.011 for patients aged ≥70 and ≥75 years, respectively). Simultaneously, the CRR revealed no increased risk of CSM for patients older than 70 and 75 years (HR = 1.2, p = 0.33 and HR = 1.53, p = 0.29, respectively).</p><p><strong>Conclusions: </strong>Elderly patients with PCa are at high risk of dying due to competing reasons, which might prevent the survival benefit of RT after RP. Selection for salvage and adjuvant RT in these individuals should be cautious.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparative evaluation of radical prostatectomy using laparoscopic and open method in view of surgical margins 腹腔镜前列腺根治术与开放前列腺根治术在手术边缘的比较分析
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.5173/ceju.2023.77
{"title":"A comparative evaluation of radical prostatectomy using laparoscopic and open method in view of surgical margins","authors":"","doi":"10.5173/ceju.2023.77","DOIUrl":"https://doi.org/10.5173/ceju.2023.77","url":null,"abstract":"","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136303777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiomics vs radiologist in bladder and renal cancer. Results from a systematic review. 放射组学与膀胱癌和肾癌的放射科医生。系统评价的结果。
IF 1.2 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.5173/ceju.2023.252
Pietro Tramanzoli, Daniele Castellani, Virgilio De Stefano, Carlo Brocca, Carlotta Nedbal, Giuseppe Chiacchio, Andrea Benedetto Galosi, Rodrigo Donalisio Da Silva, Jeremy Yuen-Chun Teoh, Ho Yee Tiong, Nithesh Naik, Bhaskar K Somani, Vineet Gauhar

Introduction: Radiomics in uro-oncology is a rapidly evolving science proving to be a novel approach for optimizing the analysis of massive data from medical images to provide auxiliary guidance in clinical issues. This scoping review aimed to identify key aspects wherein radiomics can potentially improve the accuracy of diagnosis, staging, and grading of renal and bladder cancer.

Material and methods: A literature search was performed in June 2022 using PubMed, Embase, and Cochrane Central Controlled Register of Trials. Studies were included if radiomics were compared with radiological reports only.

Results: Twenty-two papers were included, 4 were pertinent to bladder cancer, and 18 to renal cancer. Radiomics outperforms the visual assessment by radiologists in contrast-enhanced computed tomography (CECT) to predict muscle invasion but are equivalent to CT reporting by radiologists in predicting lymph node metastasis. Magnetic resonance imaging (MRI) radiomics outperforms radiological reporting for lymph node metastasis. Radiomics perform better than radiologists reporting the probability of renal cell carcinoma, improving interreader concordance and performance. Radiomics also helps to determine differences in types of renal pathology and between malignant lesions from their benign counterparts. Radiomics can be helpful to establish a model for differentiating low-grade from high-grade clear cell renal cancer with high accuracy just from contrast-enhanced CT scans.

Conclusions: Our review shows that radiomic models outperform individual reports by radiologists by their ability to incorporate many more complex radiological features.

简介:放射组学在泌尿肿瘤学中是一门快速发展的科学,被证明是一种新的方法,可以优化医学图像的大量数据分析,为临床问题提供辅助指导。本综述旨在确定放射组学可以潜在提高肾癌和膀胱癌诊断、分期和分级准确性的关键方面。材料和方法:于2022年6月使用PubMed、Embase和Cochrane Central Controlled Register of Trials进行文献检索。如果仅将放射组学与放射学报告进行比较,则纳入研究。结果:共纳入22篇论文,其中膀胱癌4篇,肾癌18篇。放射组学在预测肌肉侵袭方面优于放射科医生在对比增强计算机断层扫描(CECT)中的视觉评估,但在预测淋巴结转移方面与放射科医生的CT报告相当。磁共振成像(MRI)放射组学优于淋巴结转移的放射学报告。放射组学的表现优于放射科医生报告肾细胞癌的可能性,提高了解读者的一致性和表现。放射组学还有助于确定肾脏病理类型的差异,以及恶性病变与良性病变之间的差异。放射组学可以帮助建立一种仅通过增强CT扫描就能高精度区分低级别和高级别透明细胞肾癌的模型。结论:我们的综述表明,放射学模型在合并许多更复杂的放射学特征方面的能力优于放射科医生的个人报告。
{"title":"Radiomics vs radiologist in bladder and renal cancer. Results from a systematic review.","authors":"Pietro Tramanzoli,&nbsp;Daniele Castellani,&nbsp;Virgilio De Stefano,&nbsp;Carlo Brocca,&nbsp;Carlotta Nedbal,&nbsp;Giuseppe Chiacchio,&nbsp;Andrea Benedetto Galosi,&nbsp;Rodrigo Donalisio Da Silva,&nbsp;Jeremy Yuen-Chun Teoh,&nbsp;Ho Yee Tiong,&nbsp;Nithesh Naik,&nbsp;Bhaskar K Somani,&nbsp;Vineet Gauhar","doi":"10.5173/ceju.2023.252","DOIUrl":"https://doi.org/10.5173/ceju.2023.252","url":null,"abstract":"<p><strong>Introduction: </strong>Radiomics in uro-oncology is a rapidly evolving science proving to be a novel approach for optimizing the analysis of massive data from medical images to provide auxiliary guidance in clinical issues. This scoping review aimed to identify key aspects wherein radiomics can potentially improve the accuracy of diagnosis, staging, and grading of renal and bladder cancer.</p><p><strong>Material and methods: </strong>A literature search was performed in June 2022 using PubMed, Embase, and Cochrane Central Controlled Register of Trials. Studies were included if radiomics were compared with radiological reports only.</p><p><strong>Results: </strong>Twenty-two papers were included, 4 were pertinent to bladder cancer, and 18 to renal cancer. Radiomics outperforms the visual assessment by radiologists in contrast-enhanced computed tomography (CECT) to predict muscle invasion but are equivalent to CT reporting by radiologists in predicting lymph node metastasis. Magnetic resonance imaging (MRI) radiomics outperforms radiological reporting for lymph node metastasis. Radiomics perform better than radiologists reporting the probability of renal cell carcinoma, improving interreader concordance and performance. Radiomics also helps to determine differences in types of renal pathology and between malignant lesions from their benign counterparts. Radiomics can be helpful to establish a model for differentiating low-grade from high-grade clear cell renal cancer with high accuracy just from contrast-enhanced CT scans.</p><p><strong>Conclusions: </strong>Our review shows that radiomic models outperform individual reports by radiologists by their ability to incorporate many more complex radiological features.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/b8/CEJU-76-252.PMC10091893.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9316747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Feasibility and accuracy of prostate cancer risk calculators in prediction of prostate cancer, extraprostatic extension as well as the risk of lymph nodes metastasis. 前列腺癌风险计算器预测前列腺癌、前列腺外展及淋巴结转移风险的可行性和准确性。
IF 1.2 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.5173/ceju.2023.168
Kacper Kulik, Rafał Brzóska, Ewelina Mazurek, Magdalena Ostrowska, Adam Ostrowski, Filip Kowalski, Jacek Wilamowski, Tomasz Drewa, Jan Adamowicz, Kajetan Juszczak

Introduction: The aim of this article was to evaluate the accuracy of European Randomized study of Screening for Prostate Cancer (ERSPC 4) and Prostate Cancer Prevention Trial (PCPT 2.0) risk calculator on predicting high-grade prostate cancer (HGPCa) and accuracy of Partin and Briganti nomograms on organ confined (OC) or extraprostatic cancer (EXP), seminal vesicles invasion (SVI) and risk of lymph nodes metastasis.

Material and methods: A cohort of 269 men aged between 44-84 years, who underwent radical prostatectomy was retrospectively analysed. Based on estimated calculator risk, patients were divided into risk groups: low (LR), medium (MR) and high (HR). Results obtained with calculators were compared to post-surgical final pathology outcome.

Results: In ERPSC4, the average risk for HGPC was LR = 5%, MR = 21%, and HR = 64%. In PCPT 2.0, the average risk for HG was: LR - 8%, MR - 14%, and HR - 30%. In the final results, HGPC was observed in: LR = 29%, MR = 67%, and HR = 81%. In Partin, LNI was estimated to occur in: LR = 1%, MR = 2%, and HR = 7.5% and in Briganti: LR = 1.8%, MR = 11.4%, and HR = 44.2% while finally it was found in: LR = 1.3%, MR = 0%, and HR = 11.6%.

Conclusions: ERPSC 4 and PCPT 2.0 corresponded well with each other as well as Partin and Briganti. ERPSC 4 was more accurate in predicting HGPC than PCPT 2.0. Partin was more accurate as for LNI than Briganti. In this study group a large underestimation was observed in reference to Gleason grade.

前言:本文旨在评价欧洲前列腺癌筛查随机研究(ERSPC 4)和前列腺癌预防试验(PCPT 2.0)风险计算器预测高级别前列腺癌(HGPCa)的准确性,以及partn和Briganti nomogram预测器官局限(OC)或前列腺外癌(EXP)、精囊浸润(SVI)和淋巴结转移风险的准确性。材料和方法:回顾性分析了269例44-84岁接受根治性前列腺切除术的男性。根据估计的计算器风险,将患者分为低(LR)、中(MR)和高(HR)风险组。用计算器计算得到的结果与术后最终病理结果进行比较。结果:在ERPSC4中,HGPC的平均风险为LR = 5%, MR = 21%, HR = 64%。在PCPT 2.0中,HG的平均风险为:LR - 8%, MR - 14%, HR - 30%。在最终结果中,HGPC的发生率为:LR = 29%, MR = 67%, HR = 81%。在Partin,估计LNI发生率为:LR = 1%, MR = 2%, HR = 7.5%;在Briganti,估计LNI发生率为:LR = 1.8%, MR = 11.4%, HR = 44.2%;最后,估计LNI发生率为:LR = 1.3%, MR = 0%, HR = 11.6%。结论:erpsc4与PCPT 2.0的对应关系良好,partn与Briganti的对应关系良好。ERPSC 4预测HGPC的准确度高于PCPT 2.0。对于LNI来说,Partin比Briganti更准确。在本研究组中,观察到对Gleason分级的严重低估。
{"title":"Feasibility and accuracy of prostate cancer risk calculators in prediction of prostate cancer, extraprostatic extension as well as the risk of lymph nodes metastasis.","authors":"Kacper Kulik,&nbsp;Rafał Brzóska,&nbsp;Ewelina Mazurek,&nbsp;Magdalena Ostrowska,&nbsp;Adam Ostrowski,&nbsp;Filip Kowalski,&nbsp;Jacek Wilamowski,&nbsp;Tomasz Drewa,&nbsp;Jan Adamowicz,&nbsp;Kajetan Juszczak","doi":"10.5173/ceju.2023.168","DOIUrl":"https://doi.org/10.5173/ceju.2023.168","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this article was to evaluate the accuracy of European Randomized study of Screening for Prostate Cancer (ERSPC 4) and Prostate Cancer Prevention Trial (PCPT 2.0) risk calculator on predicting high-grade prostate cancer (HGPCa) and accuracy of Partin and Briganti nomograms on organ confined (OC) or extraprostatic cancer (EXP), seminal vesicles invasion (SVI) and risk of lymph nodes metastasis.</p><p><strong>Material and methods: </strong>A cohort of 269 men aged between 44-84 years, who underwent radical prostatectomy was retrospectively analysed. Based on estimated calculator risk, patients were divided into risk groups: low (LR), medium (MR) and high (HR). Results obtained with calculators were compared to post-surgical final pathology outcome.</p><p><strong>Results: </strong>In ERPSC4, the average risk for HGPC was LR = 5%, MR = 21%, and HR = 64%. In PCPT 2.0, the average risk for HG was: LR - 8%, MR - 14%, and HR - 30%. In the final results, HGPC was observed in: LR = 29%, MR = 67%, and HR = 81%. In Partin, LNI was estimated to occur in: LR = 1%, MR = 2%, and HR = 7.5% and in Briganti: LR = 1.8%, MR = 11.4%, and HR = 44.2% while finally it was found in: LR = 1.3%, MR = 0%, and HR = 11.6%.</p><p><strong>Conclusions: </strong>ERPSC 4 and PCPT 2.0 corresponded well with each other as well as Partin and Briganti. ERPSC 4 was more accurate in predicting HGPC than PCPT 2.0. Partin was more accurate as for LNI than Briganti. In this study group a large underestimation was observed in reference to Gleason grade.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/2f/CEJU-76-168.PMC10091896.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9316749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polish version of the Acute Cystitis Symptom Score for patients with acute uncomplicated cystitis. 波兰版急性无并发症膀胱炎患者的急性膀胱炎症状评分。
IF 1.2 Q3 Medicine Pub Date : 2023-01-01 Epub Date: 2023-03-31 DOI: 10.5173/ceju.2023.120
Kurt G Naber, Jakhongir F Alidjanov, Tomasz Blicharski, Magdalena Cerska, Waldemar Gadzinski, Jan Kawecki, Wojciech Krajewski, Pawel Miotla, Piotr Napora, Maciej Paszkowski, Slawomir Poletajew, Marcin Sieczkowski, Marcin Zaremba, Adrian Pilatz, Florian M E Wagenlehner

Introduction: The Acute Cystitis Symptom Score (ACSS) is a self-reporting questionnaire to evaluate the symptoms and quality of life in women with uncomplicated acute cystitis (AC). The aim of the current study was the additional cognitive and clinical validation of the Polish version.

Material and methods: Professional forward and backward translations from original Russian to Polish were performed by Mapi SAS. For cognitive assessment, women with different ages and educational levels were asked to comment on each item of the Polish ACSS to establish the final study version. The clinical validation was performed as a prospective, non-interventional cohort study. Women with AC (Patients) and those without (Controls) filled in the Polish ACSS during their visits to a physician's office and at a follow-up visit. Statistical analysis included ordinary descriptive values, calculation of reliability, validity, discriminative ability, responsiveness (sensitivity, specificity), and comparative analysis.

Results: The cognitive assessment was performed in 60 women with a median (range) age of 44.5 (21-88) years and different educational levels: grade school (n = 8), high school (n = 25), college (n = 22), and postgraduate education (n = 5). Forty-three patients were recruited for the clinical validation study along with 34 controls. Statistical analyses resulted in excellent values of internal consistency, discriminative ability, and validity for diagnosis of AC. At a summary score of 6 and higher in the ´Typical´ domain, positive and negative predictive values were 97% and 79%, and sensitivity and specificity were 79% and 97%, respectively.

Conclusions: The Polish version of the ACSS has demonstrated benefits for diagnosis and patient-reported outcome assessment. It is objective, fast, and cost-effective, and it may help to easily confirm the accurate diagnosis of AC. The Polish ASCSS can now be recommended for use in clinical and epidemiological studies, in clinical practice, or for self-diagnosis and patient-reported outcome in women with symptoms of AC.

引言:急性膀胱炎症状评分(ACSS)是一份自我报告问卷,用于评估无并发症急性膀胱病(AC)女性的症状和生活质量。当前研究的目的是对波兰语版本进行额外的认知和临床验证。材料和方法:由Mapi SAS进行从原始俄语到波兰语的专业正向和反向翻译。对于认知评估,不同年龄和教育水平的女性被要求对波兰ACSS的每个项目发表评论,以建立最终的研究版本。临床验证是作为一项前瞻性、非介入性队列研究进行的。患有AC的妇女(患者)和未患有AC的女性(对照组)在去医生办公室就诊和随访期间填写了波兰ACSS。统计分析包括一般描述性值、可靠性、有效性、辨别能力、反应性(敏感性、特异性)的计算和比较分析。结果:对60名女性进行了认知评估,她们的中位(范围)年龄为44.5(21-88)岁,不同的教育水平:小学(n=8)、高中(n=25)、大学(n=22)和研究生教育(n=5)。43名患者和34名对照组被纳入临床验证研究。统计分析在AC的内部一致性、辨别能力和诊断有效性方面取得了优异的结果。在“典型”领域的总分为6分及以上时,阳性和阴性预测值分别为97%和79%,敏感性和特异性分别为79%和97%。结论:波兰版ACSS已证明对诊断和患者报告的结果评估有好处。它客观、快速、成本效益高,可能有助于轻松确认AC的准确诊断。波兰ASCSS现在可以推荐用于临床和流行病学研究、临床实践,或用于AC症状女性的自我诊断和患者报告结果。
{"title":"Polish version of the Acute Cystitis Symptom Score for patients with acute uncomplicated cystitis.","authors":"Kurt G Naber,&nbsp;Jakhongir F Alidjanov,&nbsp;Tomasz Blicharski,&nbsp;Magdalena Cerska,&nbsp;Waldemar Gadzinski,&nbsp;Jan Kawecki,&nbsp;Wojciech Krajewski,&nbsp;Pawel Miotla,&nbsp;Piotr Napora,&nbsp;Maciej Paszkowski,&nbsp;Slawomir Poletajew,&nbsp;Marcin Sieczkowski,&nbsp;Marcin Zaremba,&nbsp;Adrian Pilatz,&nbsp;Florian M E Wagenlehner","doi":"10.5173/ceju.2023.120","DOIUrl":"10.5173/ceju.2023.120","url":null,"abstract":"<p><strong>Introduction: </strong>The Acute Cystitis Symptom Score (ACSS) is a self-reporting questionnaire to evaluate the symptoms and quality of life in women with uncomplicated acute cystitis (AC). The aim of the current study was the additional cognitive and clinical validation of the Polish version.</p><p><strong>Material and methods: </strong>Professional forward and backward translations from original Russian to Polish were performed by Mapi SAS. For cognitive assessment, women with different ages and educational levels were asked to comment on each item of the Polish ACSS to establish the final study version. The clinical validation was performed as a prospective, non-interventional cohort study. Women with AC (Patients) and those without (Controls) filled in the Polish ACSS during their visits to a physician's office and at a follow-up visit. Statistical analysis included ordinary descriptive values, calculation of reliability, validity, discriminative ability, responsiveness (sensitivity, specificity), and comparative analysis.</p><p><strong>Results: </strong>The cognitive assessment was performed in 60 women with a median (range) age of 44.5 (21-88) years and different educational levels: grade school (n = 8), high school (n = 25), college (n = 22), and postgraduate education (n = 5). Forty-three patients were recruited for the clinical validation study along with 34 controls. Statistical analyses resulted in excellent values of internal consistency, discriminative ability, and validity for diagnosis of AC. At a summary score of 6 and higher in the ´Typical´ domain, positive and negative predictive values were 97% and 79%, and sensitivity and specificity were 79% and 97%, respectively.</p><p><strong>Conclusions: </strong>The Polish version of the ACSS has demonstrated benefits for diagnosis and patient-reported outcome assessment. It is objective, fast, and cost-effective, and it may help to easily confirm the accurate diagnosis of AC. The Polish ASCSS can now be recommended for use in clinical and epidemiological studies, in clinical practice, or for self-diagnosis and patient-reported outcome in women with symptoms of AC.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/6c/CEJU-76-120.PMC10357829.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9864200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. D’Amico高危标准的类型和数量与病理性非器官受限前列腺癌症发病率的相关性。
IF 1.2 Q3 Medicine Pub Date : 2023-01-01 Epub Date: 2023-04-30 DOI: 10.5173/ceju.2023.030
Francesco Chierigo, Rocco Simone Flammia, Gabriele Sorce, Benedikt Hoeh, Lukas Hohenhorst, Zhe Tian, Fred Saad, Michele Gallucci, Alberto Briganti, Francesco Montorsi, Felix K H Chun, Markus Graefen, Shahrokh F Shariat, Giovanni Guano, Guglielmo Mantica, Marco Borghesi, Nazareno Suardi, Carlo Terrone, Pierre I Karakiewicz

Introduction: The aim of this study was to assess the association between the type and number of D'Amico high-risk criteria (DHRCs) with rates of pathologically non-organ-confined (NOC) prostate cancer in patients treated with radical prostatectomy (RP) and pelvic lymphadenectomy (PLND).

Material and methods: In the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 12961 RP and PLDN patients with at least one DHRC. We relied on descriptive statistics and multivariable logistic regression models.

Results: Of 12 961 patients, 6135 (47%) exclusively harboured biopsy Gleason score (GS) 8-10, 3526 (27%) had clinical stage ≥T2c, and 1234 (9.5%) had prostate-specific antigen (PSA) >20 ng/mL. Only 1886 (15%) harboured any combination of 2 DHRCs. Finally, all 3 DHRCs were present in 180 (1.4%) patients. NOC rates increased from 32% for clinical T stage ≥T2c to 49% for either GS 8-10 only or PSA >20 ng/mL only and to 66-68% for any combination of 2 DHRCs, and to 84% for respectively all 3 DHRCs, which resulted in a multivariable logistic regression OR of 1.00, 2.01 (95% CI 1.85-2.19; p <0.001), 4.16 (95% CI 3.69-4.68; p <0.001), and 10.83 (95% CI 7.35-16.52; p <0.001), respectively.

Conclusions: Our study indicates a stimulus-response effect according to the type and number of DHRCs. Hence, a formal risk-stratification within high-risk prostate cancer patients should be considered in clinical decision-making.

简介:本研究的目的是评估在接受根治性前列腺切除术(RP)和盆腔淋巴结切除术(PLND)治疗的患者中,D’Amico高危标准(DHRC)的类型和数量与病理性非器官限制性(NOC)前列腺癌症发生率之间的关系。材料和方法:在监测、流行病学和最终结果数据库(2004-2016)中,我们鉴定了12961名RP和PLDN患者至少患有一种DHRC。我们依赖描述性统计和多变量逻辑回归模型。结果:在12961例患者中,6135例(47%)患者仅具有活检Gleason评分(GS)8-10,3526例(27%)患者临床分期≥T2c,1234例(9.5%)患者前列腺特异性抗原(PSA)>20ng/mL。只有1886人(15%)携带2个DHRC的任何组合。最后,所有3个DHRC均存在于180名(1.4%)患者中。NOC发生率从临床T分期≥T2c的32%增加到仅GS8-10或PSA>20ng/mL的49%,2种DHRC的任何组合增加到66-68%,所有3种DHRC分别增加到84%,这导致了1.00的多变量逻辑回归or,2.01(95%CI 1.85-2.19;p结论:我们的研究表明,根据DHRC的类型和数量,存在刺激反应效应。因此,在临床决策中应考虑高危前列腺癌症患者的正式风险评估。
{"title":"The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer.","authors":"Francesco Chierigo,&nbsp;Rocco Simone Flammia,&nbsp;Gabriele Sorce,&nbsp;Benedikt Hoeh,&nbsp;Lukas Hohenhorst,&nbsp;Zhe Tian,&nbsp;Fred Saad,&nbsp;Michele Gallucci,&nbsp;Alberto Briganti,&nbsp;Francesco Montorsi,&nbsp;Felix K H Chun,&nbsp;Markus Graefen,&nbsp;Shahrokh F Shariat,&nbsp;Giovanni Guano,&nbsp;Guglielmo Mantica,&nbsp;Marco Borghesi,&nbsp;Nazareno Suardi,&nbsp;Carlo Terrone,&nbsp;Pierre I Karakiewicz","doi":"10.5173/ceju.2023.030","DOIUrl":"10.5173/ceju.2023.030","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to assess the association between the type and number of D'Amico high-risk criteria (DHRCs) with rates of pathologically non-organ-confined (NOC) prostate cancer in patients treated with radical prostatectomy (RP) and pelvic lymphadenectomy (PLND).</p><p><strong>Material and methods: </strong>In the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 12961 RP and PLDN patients with at least one DHRC. We relied on descriptive statistics and multivariable logistic regression models.</p><p><strong>Results: </strong>Of 12 961 patients, 6135 (47%) exclusively harboured biopsy Gleason score (GS) 8-10, 3526 (27%) had clinical stage ≥T2c, and 1234 (9.5%) had prostate-specific antigen (PSA) >20 ng/mL. Only 1886 (15%) harboured any combination of 2 DHRCs. Finally, all 3 DHRCs were present in 180 (1.4%) patients. NOC rates increased from 32% for clinical T stage ≥T2c to 49% for either GS 8-10 only or PSA >20 ng/mL only and to 66-68% for any combination of 2 DHRCs, and to 84% for respectively all 3 DHRCs, which resulted in a multivariable logistic regression OR of 1.00, 2.01 (95% CI 1.85-2.19; p <0.001), 4.16 (95% CI 3.69-4.68; p <0.001), and 10.83 (95% CI 7.35-16.52; p <0.001), respectively.</p><p><strong>Conclusions: </strong>Our study indicates a stimulus-response effect according to the type and number of DHRCs. Hence, a formal risk-stratification within high-risk prostate cancer patients should be considered in clinical decision-making.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/4e/CEJU-76-30.PMC10357822.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9864202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflection Points in Urology as Witnessed by Mark Soloway Part 1: Bladder cancer Mark Soloway见证的泌尿学拐点第一部分:膀胱癌
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.5173/ceju.2023.002e
{"title":"Inflection Points in Urology as Witnessed by Mark Soloway Part 1: Bladder cancer","authors":"","doi":"10.5173/ceju.2023.002e","DOIUrl":"https://doi.org/10.5173/ceju.2023.002e","url":null,"abstract":"","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135550680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The influence of the operator's experience on the outcomes of fusion prostate biopsy 手术经验对融合前列腺活检结果的影响
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.5173/ceju.2023.142
{"title":"The influence of the operator's experience on the outcomes of fusion prostate biopsy","authors":"","doi":"10.5173/ceju.2023.142","DOIUrl":"https://doi.org/10.5173/ceju.2023.142","url":null,"abstract":"","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135602429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Central European Journal of Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1